Founder/CEO
bit.bio
bit.bio provides a deterministic cell programming platform that converts induced pluripotent stem cells into defined human cell types at scale. Its opti-ox™ technology enables consistent production of over 50 cell types, including cardiomyocytes, hepatocytes, and neurons, for research and drug discovery applications. The company also offers custom cell development services and CRISPR screening packages.
- Biotechnology
- Drug Discovery & Therapeutics
Updated today
Funding
Raised to date
$250MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 6 rounds
+9$25M · Series D
Announced Nov 2026
Disclosed cumulative: $250M
6/6
RoundDateAmountValuationInvestors
Founders
Product
Problem
Traditional methods for producing human cells for research and therapeutic development are inconsistent, lack scalability, and suffer from donor variability, leading to unreliable experimental results and high costs. Generating specific human cell types with precision and at scale remains a significant challenge for biomedical applications.
Solution
bit.bio offers a cell coding platform that uses deterministic programming to precisely create and manufacture human cells at scale. Their opti-ox™ technology enables controlled gene expression, allowing for rapid and consistent conversion of induced pluripotent stem cells (iPSCs) into specific human cell types. This technology addresses the need for consistent and scalable cell production, providing researchers and drug developers with reliable, off-the-shelf human cell models. The resulting ioCells™ are designed for research, drug discovery, and cell-based therapies, offering functionality, consistency, and scalability. The portfolio spans more than 50 human cell types, including models of the heart, liver, and central nervous system, supporting applications in disease research, functional genomics, drug discovery, and toxicology.
Target Audience
The primary target audience includes researchers in academia and industry, drug discovery companies, and cell therapy developers seeking consistent, scalable, and functional human cell models.
Features
- opti-ox™ technology for deterministic forward programming of pluripotent stem cells (PSCs)
- Dual genomic safe harbor (GSH) approach for controlled gene expression
- Capability to create any human cell type and manufacture it at scale
- ioCells™ product line including wild-type cells, disease model cells, CRISPR-ready cells, and tracker cells
- Portfolio of over 50 human cell types including cardiomyocytes, hepatocytes, skeletal myocytes, and various neuronal and glial cells
- Custom cell development services available
- Extensive protocol library for cell culture, characterization, and assays
- Multi-cell culture protocols for co-culturing different ioCell types
- Expert-led CRISPR screening service packages